UNICREDIT BANK/CALL/BIOGEN IDEC/250/0.1/17.12.25 | Real-time BOERSE MUENCHEN 03:11:08 26/06/2024 pm IST | ||
| 3.33 EUR | 0.00% |
|
| Current month | -7.76% | ||
| 1 month | -0.30% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 26/24/26 | 3.33 | 0.00% |
| 25/24/25 | 3.33 | -4.58% |
| 24/24/24 | 3.49 | +3.25% |
| 21/24/21 | 3.38 | -2.59% |
| 20/24/20 | 3.47 | +3.27% |
Real-time BOERSE MUENCHEN
Last update June 26, 2024 at 03:11 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HD31TK |
| ISIN | DE000HD31TK8 |
| Date issued | 26/02/2024 |
| Strike | 250 $ |
| Maturity | 17/12/2025 (540 Days) |
| Parity | 10 : 1 |
| Emission price | 3.42 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.23 € |
|---|---|
| Lowest since issue | 2.16 € |
| Spread | 0.08 € |
| Spread % | 2.37% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
35
Last Close Price
223.2
USD
Average target price
283.2
USD
Spread / Average Target
+26.87%
- Stock Market
- Warrants
- Warrant
